How is Teduglutide (Gattex / Revestive) administered?
This describes how Teduglutide (Gattex / Revestive) is typically administered in clinical and research references, not a self-administration guide. The usual route is Subcutaneous, on a once daily schedule, generally over long-term in approved indication. Specific dosing is individual and beyond general information, and human evidence for Teduglutide (Gattex / Revestive) is limited.
Administration at a glance (reference data)
- Route: Subcutaneous
- Schedule: Once daily
- Cycle length: Long-term in approved indication
- Half-life: ~2 hours
References
- Teduglutide for the Treatment of Short Bowel Syndrome — Schwartz LK et al., NEJM, 2012
- Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure — Jeppesen PB, Pertkiewicz M, Messing B, et al. — Gastroenterology, 2012 (STEPS trial)
- GATTEX (teduglutide) for injection — FDA Prescribing Information — FDA / DailyMed (Takeda)
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on Teduglutide (Gattex / Revestive)
Full Teduglutide (Gattex / Revestive) breakdownTeduglutide (Gattex / Revestive) what it's used forTeduglutide (Gattex / Revestive) side effectsTeduglutide (Gattex / Revestive) mistakes to avoidTeduglutide (Gattex / Revestive) who should avoid itTeduglutide (Gattex / Revestive) half-lifeTeduglutide (Gattex / Revestive) how long to workTeduglutide (Gattex / Revestive) legal statusTeduglutide (Gattex / Revestive) how it worksAsk the AI Coach
Last updated 2026-06-15.